Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro

Cancer Letters

Volumn 329, Issue 1, 2013, Pages 17-26

  Chao, Hongtu ^a,b,c   Wang, Li ^a,b,c   Hao, Jingli ^b,c   Ni, Jie ^b,c   Chang, Lei ^b,c   Graham, Peter H ^b,c   Kearsley, John H ^b,c   Li, Yong ^b,c  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

Apoptosis; Combination therapy; Docetaxel (DTX); Epithelial ovarian cancer; LBH589 (panobinostat)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOLOGICAL MARKER; CASPASE 3; CYTOCHROME C; DOCETAXEL; HISTONE H3; HISTONE H4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; COLONY FORMING CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; INDOLES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84871722107     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.035     Document Type: Article

References (46)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Harries M., Kaye S.B. Recent advances in the treatment of epithelial ovarian cancer. Exp. Opin. Invest. Drugs 2001, 10:1715-1724.
3. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
4. Venugopal B., Evans T.R. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr. Med. Chem. 2011, 18:1658-1671.
5. Takai N., Kawamata N., Gui D., Said J.W., Miyakawa I., Koeffler H.P. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004, 101:2760-2770.
6. Takai N., Narahara H. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr. Med. Chem. 2007, 14:2548-2553.
7. Lee M.J., Kim Y.S., Kummar S., Giaccone G., Trepel J.B. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol. 2008, 20:639-649.
8. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009, 5:601-612.
9. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
10. Qian D.Z., Kato Y., Shabbeer S., Wei Y., Verheul H.M., Salumbides B., Sanni T., Atadja P., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 2006, 12:634-642.
11. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009, 280:233-241.
12. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH-589589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009, 5:601-612.
13. de Bree E., Theodoropoulos P.A., Rosing H., Michalakis J., Romanos J., Beijnen J.H., Tsiftsis D.D. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat. Rev. 2006, 32:471-482.
14. Zamboni W.C., Strychor S., Joseph E., Parise R.A., Egorin M.J., Eiseman J.L. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemother. Pharm. 2008, 62:417-426.
15. Wang L., Chen H., Liu F., Madigan M.C., Power C.A., Hao J., Patterson K.I., Pourgholami M.H., O'Brien P.M., Perkins A.C., Li Y. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett. 2011, 300:122-133.
16. 213Bi-labeled multiple targeted α radioimmunoconjugates. Prostate 2006, 66:1753-1767.
17. Hao J., Chen H., Madigan M.C., Cozzi P.J., Beretov J., Xiao W., Delprado W.J., Russell P.J., Li Y. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br. J. Cancer 2010, 103:1008-1018.
18. Zhao L., Wientjes M.G., Au J.L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res. 2004, 10:7994-8004.
19. Kuendgen A., Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110:943-954.
20. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2003, 2:721-728.
21. Qian X., LaRochelle W.J., Ara G., Wu F., Petersen K.D., Thougaard A., Sehested M., Lichenstein H.S., Jeffers M. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther. 2006, 5:2086-2095.
22. Takai N., Narahara H. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J. Oncol. 2010, 2010:458431.
23. Cooper A.L., Greenberg V.L., Lancaster P.S., van Nagell J.R., Zimmer S.G., Modesitt S.C. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol. Oncol. 2007, 104:596-601.
24. Prystowsky M.B., Adomako A., Smith R.V., Kawachi N., McKimpson W., Atadja P., Chen Q., Schlecht N.F., Parish J.L., Childs G., Belbin T.J. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J. Pathol. 2009, 218:467-477.
25. Steele N., Finn P., Brown R., Plumb J.A. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 2009, 100:758-763.
26. Fazzone W., Wilson P.M., Labonte M.J., Lenz H.J., Ladner R.D. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int. J. Cancer 2009, 125:463-473.
27. Ma Y.Y., Lin H., Moh J.S., Chen K.D., Wang I.W., Ou Y.C., You Y.S., Lung C.C. Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells, Taiwan. J. Obstet. Gynecol. 2011, 50:165-171.
28. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
29. Rathkopf D., Wong B.Y., Ross R.W., Anand A., Tanaka E., Woo M.M., Hu J., Dzik-Jurasz A., Yang W., Scher H.I. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 2010, 66:181-189.
30. Hwang J.J., Kim Y.S., Kim M.J., Kim D.E., Jeong I.G., Kim C.S. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J. Urol. 2010, 184:2557-2564.
31. Mollinedo F., Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003, 8:413-450.
32. Bissery M.C., Nohynek G., Sanderink G.J., Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs 1995, 6:339-368.
33. Miettinen S., Grenman S., Ylikomi T. Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anti-Cancer Drugs 2009, 20:267-276.
34. Tewari M., Quan L.T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D.R., Poirier G.G., Salvesen G.S., Dixit V.M. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995, 81:801-809.
35. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43.
36. Bouchard V.J., Rouleau M., Poirier G.G. PARP-1, a determinant of cell survival in response to DNA damage. Exp. Hematol. 2003, 31:446-454.
37. Mehmet H. Apoptosis: caspase find a new place to hide. Nature 2002, 403:29-30.
38. Sedlak T.W., Oltvai Z.N., Yang E., Wang K., Boise L.H., Thompson C.B., Korsmeyer S.J. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl. Acad. Sci. USA 1995, 92:7834-7838.
39. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 1998, 95:3003-3007.
40. Sak A., Stuschke M. Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin. Radiat. Oncol. 2010, 20:223-231.
41. Weberpals J.I., Koti M., Squire J.A. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet. 2011, 204:525-535.
42. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
43. Sun M., Wang G., Paciga J.E., Feldman R.I., Yuan Z.Q., Ma X.L., Shelley S.A., Jove R., Tsichlis P.N., Nicosia S.V., Cheng J.Q. AKT1/PKBa kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 2001, 159:431-437.
44. Tsuruta F., Masuyanam N., Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J. Biol. Chem. 2000, 277:14040-14047.
45. Fraser M., Bai T., Tsang B.K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int. J. Cancer 2008, 122:534-546.
46. Huang J., Zhang L., Greshock J., Colligon T.A., Wang Y., Ward R., Katsaros D., Lassus H., Butzow R., Godwin A.K., Testa J.R., Nathanson K.L., Gimotty P.A., Coukos G., Weber B.L., Degenhardt Y. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosom. Cancer 2011, 50:606-618.